Skip to content
Screener

TriSalus Life Sciences, Inc. TLSI Q3 2025 earnings

Reported November 13, 2025 · After market close

Revenue$11.6MMiss by $1.6M
EPS-$0.96Miss by $0.79
Revenue estimate$13.2M
EPS estimate-$0.17

Next report

Nov 12, 2026 (in a month)
Revenue estimate$14.0M
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Revenue$11.6M+57.4%
Gross profit$9.7M+52.2%
Operating income-$9.0M-3.1%
Net income-$10.8M-351%
EPS (diluted)-$0.96-700%

Balance sheet

See full
Cash & equivalents$23.0M+97.9%
Total debt$32.8M+51.1%
Total equity-$26.7M-30.8%
Total assets$36.5M+32.7%

Cash flow

See full
Operating cash flow-$3.7M+65.8%
CapEx$216.0K+27.8%
Free cash flow-$3.9M+64.4%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$231.88M+110%
Enterprise value$241.61M+101%
P/S5.8×+1.7×

Profitability

See full
Gross margin84%-3.1pp
Operating margin-77.7%-26.3pp
Net margin-98.4%-33.8pp
FCF margin-55.1%-22.1pp

Returns & leverage

See full
Current ratio3.1×+0.7×

FAQ

When did TriSalus Life Sciences, Inc. report Q3 2025 earnings?
TriSalus Life Sciences, Inc. (TLSI) reported Q3 2025 earnings on November 13, 2025 after market close.
What were TriSalus Life Sciences, Inc.'s Q3 2025 revenue and EPS?
TriSalus Life Sciences, Inc. reported revenue of $11.6M and eps of $-0.96 for Q3 2025.
Did TriSalus Life Sciences, Inc. beat estimates in Q3 2025?
Revenue missed the consensus estimate of $13.2M by $1.6M. EPS missed the consensus estimate of $-0.17 by $0.79.
How did TriSalus Life Sciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 57.4% from $7.3M a year earlier and eps declined 140.0% from $-0.40.
Where can I find TriSalus Life Sciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001628280-25-052008) and the 10-Q periodic report (0001628280-25-052043) directly on SEC EDGAR. The filing index links above go to sec.gov.